Sun Pharma and Pharmazz ink agreement for introducing Tyvalzi in India

Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi (Sovateltide)

Sun Pharma presents data from Phase 1 studies of GL0034

GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity

Sun Pharma and Philogen enter into an agreement for commercializing NIDLEGY

Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe

Supriya Lifescience Limited appoints of Dr. Shekhar Bhirud as President – Business Development, Strategy and R&D

USFDA puts on hold Sun Pharma trials on dermatological drug

Sun Pharma said had a teleconference call with the US Food and Drug Administration (USFDA) regarding a pulmonary embolism (serious adverse events) occurring at the 12 mg dose

Sun Pharma launches CEQUA, a novel therapy for Dry Eye Disease in India

CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology

USFDA suggests corrective measures to Sun Pharmaceutical’s Mohali facility

The USFDA had classified the inspection as "Official Action Indicated" (OAI).

Phase 3 data show Deuruxolitinib significantly improve scalp hair regrowth in Alopecia Areata

The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022

Sun Pharma completes acquisition of Concert Pharmaceuticals

The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market

Sun Pharmaceuticals to acquire minority stake in Agatsa Software and Remidio Innovative Solutions

Agasta Software is engaged in research, development and commercialization of medical devices